(Q39293482)

10 September 2017

title

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid (English)

1 reference

primary biliary cholangitis

10 September 2017

main subject

0 references

author name string

Akira Honda

1

1 reference

10 September 2017

Tadashi Ikegami

2

1 reference

10 September 2017

Makoto Nakamuta

3

1 reference

10 September 2017

Teruo Miyazaki

4

1 reference

10 September 2017

Junichi Iwamoto

5

1 reference

10 September 2017

Takeshi Hirayama

6

1 reference

10 September 2017

Yoshifumi Saito

7

1 reference

10 September 2017

Hajime Takikawa

8

1 reference

10 September 2017

Michio Imawari

9

1 reference

10 September 2017

Yasushi Matsuzaki

10

1 reference

10 September 2017

language of work or name

English

0 references

publication date

5 April 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

57

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

1931-1941

1 reference

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

10 September 2017

cites work

1 reference

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone

21 January 2018

1 reference

Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

21 January 2018

1 reference

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.

21 January 2018

1 reference

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

21 January 2018

1 reference

Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice

21 January 2018

1 reference

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/MS.

21 January 2018

1 reference

High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry

21 January 2018

1 reference

Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis

21 January 2018

1 reference

Significance of plasma 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol concentrations as markers for hepatic bile acid synthesis in cholesterol-fed rabbits

21 January 2018

1 reference

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

21 January 2018

1 reference

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

21 January 2018

1 reference

Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism

21 January 2018

1 reference

Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR.

21 January 2018

1 reference

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression

21 January 2018

1 reference

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression

21 January 2018

1 reference

Benefit of farnesoid X receptor inhibition in obstructive cholestasis

21 January 2018

1 reference

Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice

21 January 2018

1 reference

Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter.

21 January 2018

1 reference

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

21 January 2018

1 reference

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor

21 January 2018

1 reference

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

21 January 2018

1 reference

An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

21 January 2018

1 reference

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

21 January 2018

1 reference

Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle

21 January 2018

1 reference

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

21 January 2018

1 reference

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide

21 January 2018

1 reference

Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review

21 January 2018

1 reference

Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients

21 January 2018

1 reference

Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

21 January 2018

1 reference

Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population

21 January 2018

1 reference

The PXR is a drug target for chronic inflammatory liver disease

21 January 2018

1 reference

A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs

21 January 2018

1 reference

Primary biliary cirrhosis

21 January 2018

1 reference

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

7 January 2021

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

1 reference

7 January 2021

Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

7 January 2021

Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26018

1 reference

release_e2i6bayaoncujninfqmns3waji

10 September 2017

Fatcat ID

0 references

1 reference